Lewis Joseph 的 Form 4/A 修正申報
修正Tango Therapeutics, Inc.（TNGX），2023/10/17 申報
- 申報編號
- 0000895345-23-000589
- 申報時間
- 2023/10/17 19:41 ET
- 交易日
- 2023/10/13-10/16
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2023/10/17
這份申報列了 2 筆非衍生性交易。公開市場買進合計 $872.3 萬。交易後 4 天申報。
這份修正申報取代了 0000895345-23-000588（2023/10/17 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Lewis JosephCIK 0001015747 | 其他：See remarks |
| Boxer Asset Management Inc.CIK 0001465836 | 其他：See remarks |
| Boxer Capital, LLCCIK 0001465837 | 其他：See remarks |
| Davis Aaron I.CIK 0001465914 | 其他：See remarks |
| MVA Investors, LLCCIK 0001468223 | 其他：See remarks |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
- F4
These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
- F5
These securities are owned directly by Mr. Davis. Each reporting person other than Mr. Davis disclaims beneficial ownership of these securities.
- F6
These securities are owned directly by Braslyn Ltd. Mr. Lewis is the sole indirect own of Braslyn Ltd. Each reporting person other than Mr. Lewis disclaims beneficial ownership of these securities.
- F7
These securities are owned directly by BCTG Holdings, LLC ("BCTG"). Boxer Capital is the majority member of BCTG and MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Each reporting person disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
備註
The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of common stock, $0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. Boxer and Mr. Davis have informed the issuer that the purchases disclosed herein may give rise to profit subject to recovery by the issuer pursuant to Section 16(b) of the Securities Exchange Act of 1934. Without conceding the application of Section 16(b) of the Securities Exchange Act of 1934, Boxer and Mr. Davis have paid to the issuer the entire amount that would be recoverable by the issuer thereunder if the same is applicable to Boxer and Mr. Davis. As to any reporting person that is not a beneficial owner of more than 10% of the outstanding shares of Common Stock, this Form 4 shall not be deemed a concession that such person is subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer. This Form 4/A amends and restates the Form 4 filed earlier on the same date.